Safety and Efficacy of New Sirolimus-eluting Stent Models in a Preclinical Study

Three‐ and 6‐month optical coherence tomographic surveillance following percutaneous coronary intervention with the Angiolite® drug‐eluting stent: The ANCHOR study

“…The Angiolite® DES (iVascular, Barcelona, Spain) is a thin‐strut cobalt‐chromium sirolimus‐eluting stent with an open‐cell design containing a durable fluroacrylate‐based biostable polymer. A preclinical trial comparing the Angiolite DES against other contemporary DES demonstrated its superior healing properties and lower restenosis rates , supporting further prospective in vivo investigations in humans.…”

“…Although recently reported by some , “partial” strut coverage was not part of the OCT core laboratory's routine imaging protocol for evaluating stent performance. Moreover, preclinical evaluation of the Angiolite DES yielded numerically greater degrees of endothelialized stent surfaces compared with the 2nd generation Xience® DES and the 1st generation Cypher® DES systems . Furthermore, ISA rates of <1.5% are also one of the lowest reported in the literature, commensurate with the absence of an inflammatory reaction and subsequent outward remodeling that was seen with 1st generation DES systems, which created a milieu for late stent thrombosis .…”

“…Moreover, preclinical evaluation of the Angiolite DES yielded numerically greater degrees of endothelialized stent surfaces compared with the 2nd generation Xience® DES and the 1st generation Cypher® DES systems . Furthermore, ISA rates of <1.5% are also one of the lowest reported in the literature, commensurate with the absence of an inflammatory reaction and subsequent outward remodeling that was seen with 1st generation DES systems, which created a milieu for late stent thrombosis . Although limited in the duration of follow‐up coupled with relatively low overall patient numbers, the absence of stent thrombosis and myocardial infarction in ANCHOR could underscore the clinical efficacy of the Angiolite DES as a function of its quantitative OCT findings and design features.…”

“…An in vivo preclinical study (in porcine coronary arteries) evaluated Angiolite's performance against the Architect® cobalt‐chromium BMS (iVascular, Barelona, Spain), as well as the 1st generation Cypher® DES (J & J Cordis, Miami Lakes, FL) and 2nd generation Xience® (Abbott Vascular, Santa Clara, CA) DES . Quantitative coronary angiographic and histological analyses were performed 28 days following stent insertion.…”

First-in-man randomised comparison of the Angiolite durable fluoroacrylate polymer-based sirolimus-eluting stent versus a durable fluoropolymer-based everolimus-eluting stent in patients with coronary artery disease: the ANGIOLITE trial

“…This composition demonstrated in vitro early endothelial cell growth and a reduction of smooth muscle cell proliferation (Supplementary Appendix 1, Supplementary Table 1, Supplementary Table 2, Supplementary Figure 1-Supplementary Figure 5). Preclinical studies in animals have demonstrated a favourable healing process with a reduction in injury score and inflammation score that led to a reduction in neointimal area and an increase in the percentage of endothelialised surface as compared to the EES stent 7 . These preclinical results were later confirmed in the ANCHOR trial 8 that assessed strut healing after Angiolite SES implantation.…”